Mobidiag Launches Life-Saving Diagnostic Test to Improve Sepsis
Treatment in Hospitals
Prove-it(TM) Sepsis assay provides critical information for early
antimicrobial treatment review by identifying the sepsis causing
pathogens significantly earlier than current diagnostics.
Helsinki, Finland, October 30th, 2008 - Finnish biotechnology company
Mobidiag launches its first CE-marked product for In Vitro
Diagnostics (IVD) of sepsis. The microarray-based Prove-it(TM) Sepsis
is invincible in both the coverage and the rate of detecting
dangerous bacteria including the superbug MRSA from positive blood
culture samples in a single test. The test enables simultaneous
identification of 50 species in less than three hours. Based on the
excellent performance of 3300 patient samples in the University
College London Hospitals and the Hospital Districts of Helsinki and
Uusimaa (HUS, Finland) the assay is now qualified for reliable
clinical diagnostics.
"Now having the CE-IVD status our test has all the potential to
revolutionize the current hospital methodology of clinical sepsis
diagnostics," says Jaakko Pellosniemi, CEO of Mobidiag. "The
excellence of Prove-it(TM) Sepsis test combines different
technologies into an easy-to-use assay with unambiguous detection and
analysis. Moreover, our test is unique in its speed, reliability,
simplicity and the tremendous target range," Pellosniemi says.
"Sepsis or bacteremia is common and very serious condition in which
microbes have invaded the bloodstream resulting in life threatening
whole body inflammatory state," says MD, Docent Veli-Jukka Anttila
from HUS. The problem in sepsis treatment is the currently
time-consuming pathogen identification. The sooner the
effective antimicrobial treatment is started, the better for the
patient prognosis. "I believe that Mobidiag's new sepsis test is an
important step towards quicker and more precise sepsis diagnostics
helping in treatment decisions and improving the hospital hygiene,
especially in preventing the spreading of multiresistant bacteria
such as MRSA. The high specificity and sensitivity of the test are
truly convincing," Dr. Anttila states.
The Prove-it(TM) technology is a result of Mobidiag's innovative
research and development work. Release of the first CE-accepted
product opens the healthcare markets for Mobidiag. "We intend to stay
in the frontline of development and continue to play a vital role in
clinical diagnostics equally in the future," Pellosniemi concludes.
Additional information:
CEO Jaakko Pellosniemi, Mobidiag Ltd, tel. + 358 40 501 1004
Mobidiag Ltd, founded in 2001, is a Finnish biotechnology company
specialized in rapid diagnostics of life-threatening infections.
Mobidiag develops unique and innovative microarray-based Prove-it(TM)
technology which enables solid identification of multiple pathogens
simultaneously. www.mobidiag.com
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
